EX-527 significantly eliminates SIRT4 depletion-induced BTICs and xenograft formation. (A, B, C) Quantification of Hoechst SP assay (A), sphere formation efficiency (B), and CD44+/CD24- subpopulations (C) in transformed MDA-MB-468 (left) and MCF-7 cells (right panel) described in Fig. 3G with or without treatment of EX-527, a highly potent and selective inhibitor of SIRT1. (D) Immunoblotting of indicated proteins isolated from transformed MDA-MB-468 (left) and MCF-7 cells (right panel) described above with or without EX-527 treatment. (E, F) Representative ventral view images of bioluminescence from mice with injections of cells described above (E) and its quantification (F). (G) A schematic model was illustrating the biological processes regulated by SIRT4 in breast cancer. Data are means ± SEM. p < 0.01; t-test.